COMPOSITION FOR DETECTING SENILE DEMENTIA OF ALZHEIMER TYPE

COMPOSITION FOR DETECTING SENILE DEMENTIA OF ALZHEIMER TYPE

PROBLEM TO BE SOLVED: To obtain the subject composition that can be useful for diagnosis of the early step of Alzhemier's dementia by admixing a hypothalamic anterior pituitary hormone that can exert influence on mentation. SOLUTION: This composition contains a hypothalamic anterior pituitary h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: THOMAS ORTIZ ALONSO, VILA FRANCISCO RUBIA, CACABELOS RAMON
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator THOMAS ORTIZ ALONSO
VILA FRANCISCO RUBIA
CACABELOS RAMON
description PROBLEM TO BE SOLVED: To obtain the subject composition that can be useful for diagnosis of the early step of Alzhemier's dementia by admixing a hypothalamic anterior pituitary hormone that can exert influence on mentation. SOLUTION: This composition contains a hypothalamic anterior pituitary hormone, namely growth hormone-releasing factor and somatostatin. This composition can be dosed at a peptide level of about 1-10μg/kg body weight intravenously or at about 5-50μg/kg body weight subcutaneously. In addition, this composition is preferably given every day depending on the objective effect and the dosage every 6 or 12 hours is also useful. The does of the composition enables the enhancement of human metation and the detection of senile dementia of Alzhemier type by observation of neuropsychiatric response and growth hormone response.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JPH10251167A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JPH10251167A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JPH10251167A3</originalsourceid><addsrcrecordid>eNrjZLB29vcN8A_2DPH091Nw8w9ScHENcXUO8fRzVwh29fP0cQUK-Lr6hXg6Kvi7KTj6RHm4evq6BimERAa48jCwpiXmFKfyQmluBkU31xBnD93Ugvz41OKCxOTUvNSSeK8AD0MDI1NDQzNzR2Ni1AAA62opgw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPOSITION FOR DETECTING SENILE DEMENTIA OF ALZHEIMER TYPE</title><source>esp@cenet</source><creator>THOMAS ORTIZ ALONSO ; VILA FRANCISCO RUBIA ; CACABELOS RAMON</creator><creatorcontrib>THOMAS ORTIZ ALONSO ; VILA FRANCISCO RUBIA ; CACABELOS RAMON</creatorcontrib><description>PROBLEM TO BE SOLVED: To obtain the subject composition that can be useful for diagnosis of the early step of Alzhemier's dementia by admixing a hypothalamic anterior pituitary hormone that can exert influence on mentation. SOLUTION: This composition contains a hypothalamic anterior pituitary hormone, namely growth hormone-releasing factor and somatostatin. This composition can be dosed at a peptide level of about 1-10μg/kg body weight intravenously or at about 5-50μg/kg body weight subcutaneously. In addition, this composition is preferably given every day depending on the objective effect and the dosage every 6 or 12 hours is also useful. The does of the composition enables the enhancement of human metation and the detection of senile dementia of Alzhemier type by observation of neuropsychiatric response and growth hormone response.</description><edition>6</edition><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1998</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19980922&amp;DB=EPODOC&amp;CC=JP&amp;NR=H10251167A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25551,76304</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19980922&amp;DB=EPODOC&amp;CC=JP&amp;NR=H10251167A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>THOMAS ORTIZ ALONSO</creatorcontrib><creatorcontrib>VILA FRANCISCO RUBIA</creatorcontrib><creatorcontrib>CACABELOS RAMON</creatorcontrib><title>COMPOSITION FOR DETECTING SENILE DEMENTIA OF ALZHEIMER TYPE</title><description>PROBLEM TO BE SOLVED: To obtain the subject composition that can be useful for diagnosis of the early step of Alzhemier's dementia by admixing a hypothalamic anterior pituitary hormone that can exert influence on mentation. SOLUTION: This composition contains a hypothalamic anterior pituitary hormone, namely growth hormone-releasing factor and somatostatin. This composition can be dosed at a peptide level of about 1-10μg/kg body weight intravenously or at about 5-50μg/kg body weight subcutaneously. In addition, this composition is preferably given every day depending on the objective effect and the dosage every 6 or 12 hours is also useful. The does of the composition enables the enhancement of human metation and the detection of senile dementia of Alzhemier type by observation of neuropsychiatric response and growth hormone response.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1998</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB29vcN8A_2DPH091Nw8w9ScHENcXUO8fRzVwh29fP0cQUK-Lr6hXg6Kvi7KTj6RHm4evq6BimERAa48jCwpiXmFKfyQmluBkU31xBnD93Ugvz41OKCxOTUvNSSeK8AD0MDI1NDQzNzR2Ni1AAA62opgw</recordid><startdate>19980922</startdate><enddate>19980922</enddate><creator>THOMAS ORTIZ ALONSO</creator><creator>VILA FRANCISCO RUBIA</creator><creator>CACABELOS RAMON</creator><scope>EVB</scope></search><sort><creationdate>19980922</creationdate><title>COMPOSITION FOR DETECTING SENILE DEMENTIA OF ALZHEIMER TYPE</title><author>THOMAS ORTIZ ALONSO ; VILA FRANCISCO RUBIA ; CACABELOS RAMON</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JPH10251167A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1998</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>THOMAS ORTIZ ALONSO</creatorcontrib><creatorcontrib>VILA FRANCISCO RUBIA</creatorcontrib><creatorcontrib>CACABELOS RAMON</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>THOMAS ORTIZ ALONSO</au><au>VILA FRANCISCO RUBIA</au><au>CACABELOS RAMON</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPOSITION FOR DETECTING SENILE DEMENTIA OF ALZHEIMER TYPE</title><date>1998-09-22</date><risdate>1998</risdate><abstract>PROBLEM TO BE SOLVED: To obtain the subject composition that can be useful for diagnosis of the early step of Alzhemier's dementia by admixing a hypothalamic anterior pituitary hormone that can exert influence on mentation. SOLUTION: This composition contains a hypothalamic anterior pituitary hormone, namely growth hormone-releasing factor and somatostatin. This composition can be dosed at a peptide level of about 1-10μg/kg body weight intravenously or at about 5-50μg/kg body weight subcutaneously. In addition, this composition is preferably given every day depending on the objective effect and the dosage every 6 or 12 hours is also useful. The does of the composition enables the enhancement of human metation and the detection of senile dementia of Alzhemier type by observation of neuropsychiatric response and growth hormone response.</abstract><edition>6</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_JPH10251167A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title COMPOSITION FOR DETECTING SENILE DEMENTIA OF ALZHEIMER TYPE
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T10%3A38%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=THOMAS%20ORTIZ%20ALONSO&rft.date=1998-09-22&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJPH10251167A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true